New nasal spray aims to zap migraines fast

NCT ID NCT07304518

Recruiting now Symptom relief Sponsor: Sichuan Purity Pharmaceutical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether a single dose of PRT-064040 nasal spray can quickly relieve moderate to severe migraine pain and the most bothersome symptoms. About 456 adults with a history of migraines will receive either the spray or a placebo. The main goal is to see if more people are pain-free and symptom-free two hours after using the spray.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PRT-064040 nasal spray
What this could lead to: If it works, this could provide a fast-acting, non-pill option to stop migraine pain and bothersome symptoms within hours.
What could go wrong: This is an early Phase 2 trial with 456 people, so results may not apply to everyone. The spray might not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIGRAINE

Contacts and locations

Locations

The First Medical Center of PLA General Hospital
RECRUITING

Beijing, Beijing Municipality, 100039, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.